Q1 2026 OPKO Health Inc Earnings Call Transcript
Key Points
- OPKO Health Inc (OPK) made significant progress in its MODEX product development pipeline, with five programs in the clinic across vaccines, oncology, and immunology.
- The collaboration with Regeneron is advancing well, with potential total value exceeding $1 billion in milestones plus future royalties.
- The diagnostics business showed improvement, with a 3% increase in accessions per day and margin improvements due to efficiency gains.
- OPKO Health Inc (OPK) ended the quarter with a strong cash position of over $341 million, supporting ongoing operations and development plans.
- The company is on track to achieve breakeven in its diagnostics business by mid-year, reflecting successful restructuring efforts.
- First quarter revenue was below previous guidance, primarily due to delays in planned activities under the BARDA contract.
- The diagnostics business experienced a year-over-year revenue decline due to the oncology divestiture and test mix changes.
- The pharmaceutical segment reported an operating loss of $30 million, although this was an improvement from the previous year.
- BARDA funding decreased from $7 million to $4 million year-over-year, impacting revenue from infectious disease programs.
- The company continues to face challenges in achieving aggressive conversion rates for its InGenla product in the growth hormone market.
Good day and welcome to the OPCO Health First Quarter 2026 Financial Results Conference Call.
All participants will be in listen-only mode.
Should you need assistance, please signal a conference specialist by pressing the star key followed by zero.
After today's presentation, there will be an opportunity to ask questions.
To ask a question, you may press star, then one on your touchtone phone.
To withdraw your question, please press star, then two.
Please note this event is being recorded.
I would now like to turn the conference over to Yvonne Briggs.
Please go ahead.
Thank you, operator, and good afternoon. This is Yvonne Briggs with Alliance Advisors IR.
Thank you all for joining today's call to discuss Opco Health's financial results for the first quarter of 2026. I'd like to remind you that any statements made during this call by management other than statements of historical fact will be considered forward-looking and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
